Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New lymph node map could sharpen colon cancer prognosis

NCT ID NCT07380464

Knowledge-focused Sponsor: Cai Zerong Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study analyzed data from 1,500 colon cancer patients to see if a new way of classifying lymph node involvement—based on both the number and location of affected nodes and tumor deposits—can better predict survival than the current standard system. Researchers collected medical records and follow-up information to compare the two approaches. The goal is to improve how doctors estimate a patient's outlook after surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a more accurate staging system for colon cancer, helping doctors better predict patient outcomes.
What could go wrong
This is an observational study analyzing existing data, so it cannot prove that the new system improves survival. The results may not change current practice without further validation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,500 people

The number who actually took part.

Started

Mar 2010

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study enrolled a total of 1,500 participants between January 2010 and December 2022. Inclusion criteria were defined as follows: (1) a confirmed diagnosis of primary colon adenocarcinoma via auxiliary examination or pathology; (2) absence of distant metastasis (M0) verified by preoperative imaging or intraoperative findings; (3) initial radical colectomy; and (4) complete documentation of lymph node counts across three stations. Patients were excluded if they had received any form of neoadjuvant therapy (including chemotherapy, radiotherapy, immunotherapy, or targeted therapy) prior to surgery. Additionally, cases were excluded if intraoperative or postoperative pathology revealed non-malignant tumors (including carcinoma in Tis) or if patients presented with multiple primary cancers or concurrent malignancies in other sites.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Definite diagnosis of primary colon adenocarcinoma via auxiliary examination or pathology. * No distant metastasis (M0) confirmed by preoperative imaging or intraoperative findings. * No prior neoadjuvant therapy (including chemotherapy, radiotherapy, immunotherapy, or targeted therapy). * Underwent initial radical resection for colon cancer. * Available data on lymph node counts for all three stations. Exclusion Criteria: * Intraoperative or postoperative pathology confirming non-malignant tumors (including carcinoma in Tis). * Multiple primary cancers or concurrent malignancies in other sites.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colon adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colon adenocarcinoma colon carcinoma colonic neoplasm Extranodal Extension Lymphatic Metastasis metastatic malignant neoplasm in the lymph nodes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colon cancer Lymph node metastases TNM staging Tumor deposits

More trials for these conditions

Other studies related to the condition(s) this trial covers.